MATERIAL SUPPLEMENTARY

Table 1. Blocks, key points, and questions of interest proposed in the initial review of the situation of the specialty.

THEME	POINTS OF INTEREST	QUESTIONS ASKED
Scope of the	1.1. Ability to evaluate new patients and future patient reviews	 Can demand be met in the short and medium term? What about in the long term? Are the recommended times realistic and consistent with the current situation that most services are undergoing? What is needed to strengthen the service capacity in the services? What actions can be taken in this regard?
specialty	1.2. Ability to carry out preventive allergology in healthy subjects 1.3. Different pathologies that are treated, and those that	 Is the practice of preventive allergology feasible with the resources currently available? To what extent are these types of actions carried out? All equally or only secondary and tertiary prevention? What can be done to strengthen preventive activities? Should new pathologies be included in the scope of the specialty? Which? Why? Are pathologies currently treated that should not be the
	it will be possible to treat in the future 1.4. New potential allergens: pollens, animal epithelia, food, hymenoptera	 exclusive competence of the allergist? Which? How should the management of new allergens be addressed? What is important to take into account for its inclusion in the portfolio of services and usual clinical practice? Should efforts be focused on a specific allergen? Which one? Why?
	1.5. Allergology in private practice	 Is it necessary to integrate private clinical practice in the specialty forum? Why? What are the main challenges in this regard?
	2.1. Diagnostic, apparatus, and analytical methodology that will be required	 Is it necessary to adapt the minimum standards to the future demand and portfolio of services? What changes would be necessary? Is it feasible to standardise the methodology and minimum resources in all services? Is it a good idea to develop new protocols or procedures at the Society in the future?
	2.2. Portfolio of services in units, creation of units of various types of healthcare	 Is the service portfolio adapted to the real needs of the specialty? Will it be necessary to expand/reduce it? What requirements should the monographic units meet? What should the healthcare flow in these units be like? How can the creation of these be enhanced? What kind of monographic units should be prioritised? Why?
Clinical methods	2.3. Time to reach a diagnosis	 Are the average diagnostic times acceptable and consistent with the healthcare situation? What measures need be implemented to reduce the diagnostic time? How could more first episodes of pathologies such as asthma or rhinoconjunctivitis be captured? Is capturing these first episodes important for the development of the specialty to improve control of the disease due to early

J Investig Allergol Clin Immunol 2020; Vol. 31(2): 120-131

© 2021 Esmon Publicidad

doi: 10.18176/jiaci.0473

		diagnosis?
	2.4. Intolerance	
	management without	 Are the necessary resources available to address this health problem? Should it be done exclusively from
	immune mechanism	
	minune mechanism	allergology or should it involve other specialties? • Should the usual assistance procedures be adapted to
		procedures of deapted to
		meet the demand for intolerances, especially food?
		• How can the diagnosis of these intolerances be
	0.5 W 1: .	improved?
	2.5. Waiting list	• Are these waiting times reasonable? Are changes
		expected in the short to medium term? How could they
		be improved?
		• What actions could be taken to reduce or end the
		differences between Regional Governments?
		• What should the standard waiting time be in order to
	2.1 41.114 4 1.11.11	achieve optimal patient care?
	3.1. Ability to decide in	• Is the importance of the allergist in decision-making
	opposition to other	during treatment of allergy patients well defined?
	specialties	• How does interaction with other specialties involved in
		the management of the allergy patient take place?
		• Should models of relationship with other specialties that
	2.2 Dunamintian	aim to optimise patient treatment be developed?
	3.2. Prescription	• Is the use of the prescription of biological medicines
	biological treatments	established in the usual clinical practice? What are the main barriers when prescribing biological
		what are the main partiers when presenting biological
		treatments? Is it necessary to implement new strategies in
		• Is it necessary to implement new strategies in allergology to ensure access to these treatments?
		 Has the use of biological medicines in the management
		of severe allergic asthma and other allergy-associated
Treatment.		diseases been established?
1100001101101	3.3. Allergen	How should the specialty address future perspectives in
	immunotherapy	immunotherapy?
	in i	• What role should the allergist play in the administration
		of these types of treatments?
		• Is it necessary to adapt the resources or protocols of the
		different services to offer these types of treatments to
		patients optimally?
		• What specific resources are necessary for the optimal
		what specific resources are necessary for the optimal
		development of immunotherapy?
	3.4. Future treatments	development of immunotherapy?Has the allergist been informed about the therapies that
	3.4. Future treatments	 development of immunotherapy? Has the allergist been informed about the therapies that are still to come?
	3.4. Future treatments	 development of immunotherapy? Has the allergist been informed about the therapies that are still to come? Are enough clinical trials conducted in Spain to develop
	3.4. Future treatments	 development of immunotherapy? Has the allergist been informed about the therapies that are still to come? Are enough clinical trials conducted in Spain to develop new treatments?
	3.4. Future treatments	 development of immunotherapy? Has the allergist been informed about the therapies that are still to come? Are enough clinical trials conducted in Spain to develop new treatments? Do developing treatments cover real needs of allergy
		 development of immunotherapy? Has the allergist been informed about the therapies that are still to come? Are enough clinical trials conducted in Spain to develop new treatments? Do developing treatments cover real needs of allergy patients?
	4.1. Multidisciplinary	 development of immunotherapy? Has the allergist been informed about the therapies that are still to come? Are enough clinical trials conducted in Spain to develop new treatments? Do developing treatments cover real needs of allergy patients? Should the start-up of these units be enhanced? For
		 development of immunotherapy? Has the allergist been informed about the therapies that are still to come? Are enough clinical trials conducted in Spain to develop new treatments? Do developing treatments cover real needs of allergy patients? Should the start-up of these units be enhanced? For which pathologies?
Inda 1	4.1. Multidisciplinary	 development of immunotherapy? Has the allergist been informed about the therapies that are still to come? Are enough clinical trials conducted in Spain to develop new treatments? Do developing treatments cover real needs of allergy patients? Should the start-up of these units be enhanced? For which pathologies? What should the minimum requirements of these units
Integral	4.1. Multidisciplinary	 development of immunotherapy? Has the allergist been informed about the therapies that are still to come? Are enough clinical trials conducted in Spain to develop new treatments? Do developing treatments cover real needs of allergy patients? Should the start-up of these units be enhanced? For which pathologies? What should the minimum requirements of these units be? Should own protocols be developed in co-operation
approach to	4.1. Multidisciplinary	 development of immunotherapy? Has the allergist been informed about the therapies that are still to come? Are enough clinical trials conducted in Spain to develop new treatments? Do developing treatments cover real needs of allergy patients? Should the start-up of these units be enhanced? For which pathologies? What should the minimum requirements of these units be? Should own protocols be developed in co-operation with the other specialties of the unit?
_	4.1. Multidisciplinary	 development of immunotherapy? Has the allergist been informed about the therapies that are still to come? Are enough clinical trials conducted in Spain to develop new treatments? Do developing treatments cover real needs of allergy patients? Should the start-up of these units be enhanced? For which pathologies? What should the minimum requirements of these units be? Should own protocols be developed in co-operation with the other specialties of the unit? What should the flow of patients, decisions, and
approach to	4.1. Multidisciplinary Units	 development of immunotherapy? Has the allergist been informed about the therapies that are still to come? Are enough clinical trials conducted in Spain to develop new treatments? Do developing treatments cover real needs of allergy patients? Should the start-up of these units be enhanced? For which pathologies? What should the minimum requirements of these units be? Should own protocols be developed in co-operation with the other specialties of the unit? What should the flow of patients, decisions, and communications in these units be like?
approach to	4.1. Multidisciplinary Units 4.2. Origin of the	 development of immunotherapy? Has the allergist been informed about the therapies that are still to come? Are enough clinical trials conducted in Spain to develop new treatments? Do developing treatments cover real needs of allergy patients? Should the start-up of these units be enhanced? For which pathologies? What should the minimum requirements of these units be? Should own protocols be developed in co-operation with the other specialties of the unit? What should the flow of patients, decisions, and communications in these units be like? Is it derived from other specialties enough? And from
approach to	4.1. Multidisciplinary Units	 development of immunotherapy? Has the allergist been informed about the therapies that are still to come? Are enough clinical trials conducted in Spain to develop new treatments? Do developing treatments cover real needs of allergy patients? Should the start-up of these units be enhanced? For which pathologies? What should the minimum requirements of these units be? Should own protocols be developed in co-operation with the other specialties of the unit? What should the flow of patients, decisions, and communications in these units be like? Is it derived from other specialties enough? And from Primary Care?
approach to	4.1. Multidisciplinary Units 4.2. Origin of the	 development of immunotherapy? Has the allergist been informed about the therapies that are still to come? Are enough clinical trials conducted in Spain to develop new treatments? Do developing treatments cover real needs of allergy patients? Should the start-up of these units be enhanced? For which pathologies? What should the minimum requirements of these units be? Should own protocols be developed in co-operation with the other specialties of the unit? What should the flow of patients, decisions, and communications in these units be like? Is it derived from other specialties enough? And from Primary Care? How could the bypass circuits be improved
approach to	4.1. Multidisciplinary Units 4.2. Origin of the	 development of immunotherapy? Has the allergist been informed about the therapies that are still to come? Are enough clinical trials conducted in Spain to develop new treatments? Do developing treatments cover real needs of allergy patients? Should the start-up of these units be enhanced? For which pathologies? What should the minimum requirements of these units be? Should own protocols be developed in co-operation with the other specialties of the unit? What should the flow of patients, decisions, and communications in these units be like? Is it derived from other specialties enough? And from Primary Care? How could the bypass circuits be improved (ordinary/preferred)?
approach to	4.1. Multidisciplinary Units 4.2. Origin of the	 development of immunotherapy? Has the allergist been informed about the therapies that are still to come? Are enough clinical trials conducted in Spain to develop new treatments? Do developing treatments cover real needs of allergy patients? Should the start-up of these units be enhanced? For which pathologies? What should the minimum requirements of these units be? Should own protocols be developed in co-operation with the other specialties of the unit? What should the flow of patients, decisions, and communications in these units be like? Is it derived from other specialties enough? And from Primary Care? How could the bypass circuits be improved (ordinary/preferred)? Is it necessary to carry out training in certain
approach to	4.1. Multidisciplinary Units 4.2. Origin of the	 development of immunotherapy? Has the allergist been informed about the therapies that are still to come? Are enough clinical trials conducted in Spain to develop new treatments? Do developing treatments cover real needs of allergy patients? Should the start-up of these units be enhanced? For which pathologies? What should the minimum requirements of these units be? Should own protocols be developed in co-operation with the other specialties of the unit? What should the flow of patients, decisions, and communications in these units be like? Is it derived from other specialties enough? And from Primary Care? How could the bypass circuits be improved (ordinary/preferred)? Is it necessary to carry out training in certain specialties/PA to encourage optimal referral? What
approach to	4.1. Multidisciplinary Units 4.2. Origin of the	 development of immunotherapy? Has the allergist been informed about the therapies that are still to come? Are enough clinical trials conducted in Spain to develop new treatments? Do developing treatments cover real needs of allergy patients? Should the start-up of these units be enhanced? For which pathologies? What should the minimum requirements of these units be? Should own protocols be developed in co-operation with the other specialties of the unit? What should the flow of patients, decisions, and communications in these units be like? Is it derived from other specialties enough? And from Primary Care? How could the bypass circuits be improved (ordinary/preferred)? Is it necessary to carry out training in certain

J Investig Allergol Clin Immunol 2020; Vol. 31(2): 120-131 doi: 10.18176/jiaci.0473

	logoties, hereited	levels of some there-there the action of the first
Resources	location: hospital, outpatient, hospitalisation, day hospital 5.2. Specialists needed in the future	 levels of care throughout the entire care flow of the patient also appropriate? How could it be improved? What is the ideal place to properly treat and cater for patients? Where will the healthcare take place in the future? Where should it take place? How can we cope with the lack of specialists in the specialty? What measures can be carried out to meet the needs of patients and meet the demand? What future will the specialty have if concrete actions to
	5.3. Units and staff	solve this problem are not taken?Are the necessary resources available? What needs do
	needed to care for	the units have in the short term?
	patients	• Is it necessary to develop an action plan to solve this problem? What actions could be carried out?
	6.1. Training of	What skills should an allergist acquire to face the new
	specialists in the future	challenges?
		How can homogeneity be guaranteed in the training of specialists in all Regional Governments?
		What should be the objectives of the specialty in terms
		of improving and enhancing the training of specialists?
	6.2. Pre and	Is the official allergy specialty programme in force
Transianian	postgraduate teaching	adequate? Is a review necessary?
Training, teaching, and		• Is it necessary to establish a training plan for future re- accreditation?
research		How can undergraduate and postgraduate teaching be
		promoted in different services and universities? Are
		additional resources necessary?
	6.3. Research	How can research be encouraged?
		• What lines of research should be enhanced in the future?
		Would it be necessary to involve personnel with
		exclusive dedication to research work, including
		teachers?
	7.1. Age of our future	• What patients do we expect to attend in the medium and
	patients	long term? How will the age of new patients affect clinical
		How will the age of new patients affect clinical practice?
		• Will it be necessary to adapt the methods and resources?
		How?
.	7.2. Geographic	Will geographic distribution be a determining factor in
Patients	distribution of new	the allergic care of the future? Why?
	patients	How can distribution affect the course and diagnosis of pathologies?
		 Should we develop any specific action in this regard?
	7.3. Effects on the	How can the quality of life of people affected by
	quality of life of	allergic processes be improved?
	allergy sufferers, loss	• What can be done in the specialty to minimise the
	of productivity, absenteeism, and	impact of the disease on patient performance?Would it be advisable to develop training programmes
	presentism (going to	• Would it be advisable to develop training programmes aimed at the society and/or other preventive measures?
	work when ill)	providence in the state of the

J Investig Allergol Clin Immunol 2020; Vol. 31(2): 120-131 © 2021 Esmon Publicidad doi: 10.18176/jiaci.0473

Table 2. Thematic blocks agreed by the scientific committee and members responsible for coordinating and identifying challenges and solutions for each of them.

THEMATIC BLOCK	COORDINATOR	COLLABORATORS
1. Superspecialisation, multidisciplinary units,	Dr. Antonio Valero	Dr. Teresa Dordal
and change of the care model		Dr. Julio Delgado
		Dr. Pablo Rodríguez del Río
		Dr. Manuel Rial
		Dr. Carlos Colás
2. Definition of services portfolio	Dr. Javier Montoro	Dr. Dolores Hernández
(pathologies) and technical advancement and		Dr. Juan Fraj
updating of diagnostic methods		Dr. Monica Anton
		Dr. Álvaro Moreno
		Dr. Aida Gómez Cardeñosa
3. Qualification of therapeutic tools	Dr. Santiago Quirce	Dr. Javier Dominguez
(immunotherapy) and adaptation of new		Dr. Silvia Sánchez
treatments		Dr. David González
		Dr. Stefan Cimbollek
4. Nursing training and stabilisation	Dr. Joaquín Sastre	Ms. Cristina Mañas
		Ms. María José García
		Ms. Amparo Gaitano
5. Undergraduate and postgraduate training,	Dr. Carmen Vidal	Dr. Teresa Carrillo
and talent attraction	Dr. Ignacio Dávila	Dr. Luis Prieto
		Dr. Óscar Palomares
6. Clinical practice homogenisation,	Dr. José María	Dr. Eduardo Fernández
accreditation, and recertification (services and	Olaguibel	Dr. María José Álvarez
professionals)		Dr. Gabriela Zambrano
		Dr. Beatriz Pola
7. Research professionalisation	Dr. María José Torres	Dr. Joan Bartra
		Dr. Marta Ferrer
		Dr. Ibón Eguíluz
8. Alliances with patients and patient	Dr. Carmen Vidal	Dr. Ignacio Esteban
associations	Dr. Virginia	Dr. Javier Contreras
	Rodriguez	Dr. Carmen Moreno
9. Communication strategies, new	Dr. Darío Antolin	Dr. Alberto Álvarez
technologies, and internationalisation		Dr. Virginia Bellido
		Dr. Rosa María Muñoz
10. Allergology in private practice	Dr. Pedro Ojeda	Dr. Juan Manuel Igea
		Dr. Paula Mendez
		Dr. Agustín Fernández
		Dr. Teresa Posadas

J Investig Allergol Clin Immunol 2020; Vol. 31(2): 120-131 doi: 10.18176/jiaci.0473

Table 3. Main sociodemographic characteristics of the participants in the validation survey.

	15.50 (1.55)
Years of experience (average, n)	17.73 (167)
Age (mean, n)	47.16 (166)*
Gender (%, n)	
Male	28.1 (47)
Female	71.9 (120)
Charge (%, n)	
Head of service/section/unit	29.3 (49)
Attending doctor	70.7 (118)
Work centre (%, n)	
Private hospital	18.6 (31)
Public hospital	70.7 (118)
Both of them	10.8 (18)
Type of centre (%, n)	
Reference hospital	73.7 (123)
Regional hospital	26.3 (44)
Regional Government (%, n)	
Andalusia	16.2 (27)
Aragon	1.8 (3)
Canary Islands	4.8 (8)
Cantabria	1.8 (3)
Castilla y Leon	2.4 (4)
Castilla La Mancha	4.8 (8)
Catalonia	12.6 (21)
Community of Madrid	26.9 (45)
Autonomous Community of Navarre	2.4 (4)
Valencian Regional Government	7.8 (13)
Extremadura	7.8 (13)
Galicia	4.2 (7)
Balearic Islands	0.6 (1)
La Rioja	0.6 (1)
Basque Country	1.2 (2)
Principality of Asturias	1.2 (2)
Murcia Region	3.0 (5)

^{*}Data lost in the system.

J Investig Allergol Clin Immunol 2020; Vol. 31(2): 120-131 doi: 10.18176/jiaci.0473